James L Januzzi

List of Publications by Year
in descending order

566 papers	65,916 citations	2311 98 h-index	906 241 g-index
576 all docs	576 docs citations	576 times ranked	45577 citing authors

#	Article	IF	Citations
1	2013 ACCF/AHA Guideline for the Management of HeartÂFailure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	1.2	7,017
2	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	13.9	2,821
3	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807
4	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
5	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	1.0	2,687
6	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	1.2	2,558
7	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	1.0	2,447
8	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
9	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	13.9	2,143
10	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine, 2017, 377, 1513-1524.	13.9	1,099
11	The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study. American Journal of Cardiology, 2005, 95, 948-954.	0.7	1,046
12	NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. European Heart Journal, 2006, 27, 330-337.	1.0	978
13	Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease. Circulation, 2009, 119, 2545-2552.	1.6	747
14	Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab. Circulation: Cardiovascular Imaging, 2012, 5, 596-603.	1.3	653
15	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	2.9	630
16	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 772-810.	1.2	612
17	Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. Journal of the American College of Cardiology, 2020, 76, 533-546.	1.2	592
18	Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients. American Journal of Cardiology, 2011, 107, 1375-1380.	0.7	577

#	Article	IF	Citations
19	Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2006, 48, 1217-1224.	1.2	500
20	Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea. Journal of the American College of Cardiology, 2007, 50, 607-613.	1.2	461
21	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 2019, 21, 715-731.	2.9	446
22	Characterizing the young patient with aortic dissection: results from the international registry of aortic dissection (IRAD). Journal of the American College of Cardiology, 2004, 43, 665-669.	1.2	443
23	Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab. Journal of the American College of Cardiology, 2014, 63, 809-816.	1.2	438
24	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2017, 135, e1054-e1091.	1.6	417
25	Prognostic Utility of Novel Biomarkers of Cardiovascular Stress. Circulation, 2012, 126, 1596-1604.	1.6	414
26	Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1085.	3.8	403
27	Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 488.	3.8	391
28	Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	3.8	386
29	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	0.7	362
30	Renal Function, Congestive Heart Failure, and Amino-Terminal Pro-Brain Natriuretic Peptide Measurement. Journal of the American College of Cardiology, 2006, 47, 91-97.	1.2	356
31	Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1458-1465.	1.2	335
32	Use of Amino-Terminal Pro–B-Type Natriuretic Peptide to Guide Outpatient Therapy of Patients With Chronic Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology, 2011, 58, 1881-1889.	1.2	323
33	Cardiac Troponin for Assessment of Myocardial Injury in COVID-19. Journal of the American College of Cardiology, 2020, 76, 1244-1258.	1.2	322
34	N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure. Circulation, 2007, 115, 3103-3110.	1.6	299
35	Biomarkers and diagnostics in heart failure. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2442-2450.	1.8	298
36	Galectin–3, cardiac structure and function, and long–term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure, 2010, 12, 826-832.	2.9	282

#	Article	IF	Citations
37	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2013, 62, 1495-1539.	1.2	276
38	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 2020, 76, 1117-1145.	1.2	276
39	Inflammation in Heart Failure. Journal of the American College of Cardiology, 2020, 75, 1324-1340.	1.2	273
40	Depression and Cardiac Disease: Epidemiology, Mechanisms, and Diagnosis. Cardiovascular Psychiatry and Neurology, 2013, 2013, 1-14.	0.8	266
41	Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. European Heart Journal, 2012, 33, 2265-2271.	1.0	256
42	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 72, 3200-3223.	1.2	251
43	Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. American Heart Journal, 2005, 149, 744-750.	1.2	239
44	2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 71, 201-230.	1.2	235
45	Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 2411.	3.8	232
46	Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. European Heart Journal, 2014, 35, 1559-1567.	1.0	229
47	Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. European Journal of Heart Failure, 2011, 13, 718-725.	2.9	228
48	Emerging Biomarkers in Heart Failure. Clinical Chemistry, 2012, 58, 127-138.	1.5	227
49	Red blood cell distribution width and 1 year mortality in acute heart failure. European Journal of Heart Failure, 2010, 12, 129-136.	2.9	224
50	Utility of Amino-Terminal Pro–Brain Natriuretic Peptide Testing for Prediction of 1-Year Mortality in Patients With Dyspnea Treated in the Emergency Department. Archives of Internal Medicine, 2006, 166, 315.	4.3	218
51	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation, 2021, 143, 337-349.	1.6	217
52	The Biology of ST2: The International ST2 Consensus Panel. American Journal of Cardiology, 2015, 115, 3B-7B.	0.7	216
53	Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma â€" The Presageâ„¢ ST2 assay. Clinica Chimica Acta, 2009, 409, 33-40.	0.5	214
54	Natriuretic Peptide Testing in Heart Failure. Circulation, 2011, 123, 2015-2019.	1.6	214

#	Article	IF	Citations
55	Body Mass Index and Mortality in Acutely Decompensated Heart Failure Across the World. Journal of the American College of Cardiology, 2014, 63, 778-785.	1.2	213
56	Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. International Journal of Cardiology, 2013, 168, 2186-2194.	0.8	207
57	Established and Emerging Roles of Biomarkers in Heart Failure. Circulation Research, 2018, 123, 614-629.	2.0	200
58	Biology of the Natriuretic Peptides. American Journal of Cardiology, 2008, 101, S3-S8.	0.7	190
59	Increases of Cardiac Troponin in Conditions other than Acute Coronary Syndrome and Heart Failure. Clinical Chemistry, 2009, 55, 2098-2112.	1.5	187
60	Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 215.	3.0	186
61	Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure. Journal of Cardiac Failure, 2008, 14, 732-738.	0.7	179
62	Iatrogenic aortic dissection. American Journal of Cardiology, 2002, 89, 623-626.	0.7	177
63	Left Ventricular Thrombus After Acute Myocardial Infarction. JAMA Cardiology, 2018, 3, 642.	3.0	171
64	Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. JACC: Heart Failure, 2014, 2, 65-72.	1.9	167
65	High-Sensitivity Troponin T Concentrations in Acute Chest Pain Patients Evaluated With Cardiac Computed Tomography. Circulation, 2010, 121, 1227-1234.	1.6	163
66	Distribution and Clinical Correlates of the Interleukin Receptor Family Member Soluble ST2 in the Framingham Heart Study. Clinical Chemistry, 2012, 58, 1673-1681.	1.5	162
67	Collaborative Care for Depression and Anxiety Disorders in Patients With Recent Cardiac Events. JAMA Internal Medicine, 2014, 174, 927.	2.6	161
68	Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea. Circulation: Heart Failure, 2009, 2, 311-319.	1.6	160
69	Natriuretic peptide-guided heart failure management. European Heart Journal, 2014, 35, 16-24.	1.0	159
70	Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock*. Critical Care Medicine, 2004, 32, 1643-1647.	0.4	157
71	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation, 2018, 137, 286-297.	1.6	157
72	Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. JACC: Heart Failure, 2018, 6, 273-285.	1.9	152

#	Article	IF	Citations
73	State of the Art: Newer biomarkers in heart failure. European Journal of Heart Failure, 2015, 17, 559-569.	2.9	151
74	Soluble Urokinase Receptor and Acute Kidney Injury. New England Journal of Medicine, 2020, 382, 416-426.	13.9	149
75	Serum albumin and mortality in acutely decompensated heart failure. American Heart Journal, 2010, 160, 1149-1155.	1.2	148
76	A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. Journal of the American College of Cardiology, 2002, 39, 1518-1523.	1.2	145
77	Renal Clearance of B-Type Natriuretic Peptide and Amino Terminal Pro-B-Type Natriuretic Peptide. Journal of the American College of Cardiology, 2009, 53, 884-890.	1.2	142
78	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. Journal of the American College of Cardiology, 2017, 70, 704-712.	1.2	142
79	The potential role and rationale for treatment of heart failure with sodium–glucose co–transporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	2.9	139
80	Amino-Terminal Pro-Brain Natriuretic Peptide, Renal Function, and Outcomes in Acute Heart Failure. Journal of the American College of Cardiology, 2006, 48, 1621-1627.	1.2	136
81	Heart failure with reduced ejection fraction. Nature Reviews Disease Primers, 2017, 3, 17058.	18.1	136
82	N-Terminal Pro–B-Type Natriuretic Peptide in the Emergency Department. Journal of the American College of Cardiology, 2018, 71, 1191-1200.	1.2	136
83	Clinical Implications of the New York Heart Association Classification. Journal of the American Heart Association, 2019, 8, e014240.	1.6	133
84	Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. European Heart Journal, 2012, 33, 2197-2205.	1.0	130
85	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. American Heart Journal, 2014, 167, 853-860.e4.	1.2	128
86	NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. European Heart Journal, 2006, 27, 839-845.	1.0	127
87	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 280-286.	1.9	127
88	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology, 2018, 72, 2309-2320.	1.2	126
89	Interpreting Cardiac Troponin Results from High-Sensitivity Assays in Chronic Kidney Disease without Acute Coronary Syndrome. Clinical Chemistry, 2012, 58, 1342-1351.	1.5	125
90	Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro–Brain Natriuretic Peptide in Patients With Acute Dyspnea. Archives of Internal Medicine, 2007, 167, 400.	4.3	125

#	Article	IF	Citations
91	Are Serial BNP Measurements Useful in Heart Failure Management?. Circulation, 2013, 127, 500-508.	1.6	124
92	Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). American Journal of Cardiology, 2002, 90, 1246-1249.	0.7	118
93	Cocaine and Marijuana Use Among YoungÂAdults With Myocardial Infarction. Journal of the American College of Cardiology, 2018, 71, 2540-2551.	1.2	118
94	Soluble Concentrations of the Interleukin Receptor Family Member ST2 and Î²-Blocker Therapy in Chronic Heart Failure. Circulation: Heart Failure, 2013, 6, 1206-1213.	1.6	116
95	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212.	1.0	114
96	Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling inÂHeartÂFailure With ReducedÂEjectionÂFraction. JACC: Heart Failure, 2019, 7, 782-794.	1.9	113
97	Association Between Elevated Blood Glucose and Outcome in Acute Heart Failure. Journal of the American College of Cardiology, 2013, 61, 820-829.	1.2	111
98	Clinical and Prognostic Significance of sST2 in HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2193-2203.	1.2	110
99	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care, 2022, 45, 1670-1690.	4.3	109
100	The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine, 2022, 28, 809-813.	15.2	107
101	Rationale and Design of theÂGUIDE-ITÂStudy. JACC: Heart Failure, 2014, 2, 457-465.	1.9	106
102	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193.	1.6	106
103	The Effects of Ejection Fraction on N-Terminal ProBNP and BNP Levels in Patients With Acute CHF: Analysis From the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Journal of Cardiac Failure, 2005, 11, S9-S14.	0.7	105
104	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	1.9	104
105	Usefulness of Intermediate Amino-Terminal Pro-Brain Natriuretic Peptide Concentrations for Diagnosis and Prognosis of Acute Heart Failure. American Journal of Cardiology, 2006, 98, 386-390.	0.7	103
106	Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary careâ€. European Heart Journal, 2010, 31, 1881-1889.	1.0	103
107	Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy. JACC: Heart Failure, 2013, 1, 480-487.	1.9	103
108	Heart Failure With Preserved Ejection Fraction Expert Panel Report. JACC: Heart Failure, 2018, 6, 619-632.	1.9	103

#	Article	IF	Citations
109	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. Journal of the American College of Cardiology, 2019, 73, 1059-1077.	1.2	103
110	Serial measurement of galectinâ€3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. European Journal of Heart Failure, 2013, 15, 1157-1163.	2.9	102
111	Prescriber Patterns ofÂSGLT2i After Expansions of U.S.ÂFoodÂand Drug Administration Labeling. Journal of the American College of Cardiology, 2018, 72, 3370-3372.	1.2	102
112	Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. Journal of Clinical Investigation, 2013, 123, 4208-4218.	3.9	101
113	Effect of Neprilysin Inhibition on VariousÂNatriuretic Peptide Assays. Journal of the American College of Cardiology, 2019, 73, 1273-1284.	1.2	98
114	Which heart failure patients profit from natriuretic peptide guided therapy? A metaâ€analysis from individual patient data of randomized trials. European Journal of Heart Failure, 2015, 17, 1252-1261.	2.9	95
115	Clinical Uncertainty, Diagnostic Accuracy, and Outcomes in Emergency Department Patients Presenting With Dyspnea. Archives of Internal Medicine, 2008, 168, 741.	4.3	94
116	ST2: A Novel Remodeling Biomarker in Acute and Chronic Heart Failure. Current Heart Failure Reports, 2010, 7, 9-14.	1.3	93
117	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPERORâ€Preserved trial. European Journal of Heart Failure, 2020, 22, 2383-2392.	2.9	93
118	Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. International Journal of Cardiology, 2015, 184, 337-343.	0.8	92
119	Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensityâ€score matched study. European Journal of Heart Failure, 2018, 20, 345-354.	2.9	92
120	Biomarkers of Cardiovascular Stress and Incident Chronic Kidney Disease. Clinical Chemistry, 2013, 59, 1613-1620.	1.5	91
121	Predictors and outcomes of heart failure with midâ€range ejection fraction. European Journal of Heart Failure, 2018, 20, 651-659.	2.9	91
122	Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. European Heart Journal, 2014, 35, 3434-3441.	1.0	90
123	Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. Circulation, 2017, 135, 116-127.	1.6	90
124	Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency. Circulation, 2002, 105, 2361-2366.	1.6	89
125	Cost-Effectiveness of Using N-Terminal Pro-Brain Natriuretic Peptide to Guide the Diagnostic Assessment and Management of Dyspneic Patients in the Emergency Department. American Journal of Cardiology, 2006, 98, 800-805.	0.7	88
126	Effects of Optimism and Gratitude on Physical Activity, Biomarkers, and Readmissions After an Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 55-63.	0.9	86

#	ARTICLE	IF	CITATIONS
127	Amino-Terminal Proâ€"B-Type Natriuretic Peptide Testing for the Diagnosis or Exclusion of Heart Failure in Patients with Acute Symptoms. American Journal of Cardiology, 2008, 101, S29-S38.	0.7	85
128	Relation between soluble ST2, growth differentiation factorâ€"15, and high-sensitivity troponin I and incident atrial fibrillation. American Heart Journal, 2014, 167, 109-115.e2.	1.2	85
129	A Positive Psychology Intervention for Patients with an Acute Coronary Syndrome: Treatment Development and Proof-of-Concept Trial. Journal of Happiness Studies, 2016, 17, 1985-2006.	1.9	84
130	Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays. JAMA Cardiology, 2019, 4, 1034.	3.0	84
131	Impact of a Depression Care Management Program for Hospitalized Cardiac Patients. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 198-205.	0.9	83
132	Cardiovascular Risk Factors Are Associated With Future Cancer. JACC: CardioOncology, 2021, 3, 48-58.	1.7	83
133	Charting a Roadmap for Heart Failure Biomarker Studies. JACC: Heart Failure, 2014, 2, 477-488.	1.9	81
134	ST2 Testing for Chronic Heart Failure Therapy Monitoring: The International ST2 Consensus Panel. American Journal of Cardiology, 2015, 115, 70B-75B.	0.7	80
135	Soluble ST2 in Heart Failure. Heart Failure Clinics, 2018, 14, 41-48.	1.0	80
136	Misclassification of Myocardial Injury as Myocardial Infarction. JAMA Cardiology, 2019, 4, 460.	3.0	80
137	ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside. Journal of Cardiovascular Translational Research, 2013, 6, 493-500.	1.1	77
138	Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33/ST2 Signaling in Left Ventricular SystolicÂDysfunction After AcuteÂMyocardial Infarction. JACC: Heart Failure, 2015, 3, 50-58.	1.9	77
139	Plasma C-Reactive Protein Levels Are Associated With Improved Outcome in ARDS. Chest, 2009, 136, 471-480.	0.4	75
140	ST2 and Prognosis in Acutely Decompensated Heart Failure: TheÂInternational ST2 Consensus Panel. American Journal of Cardiology, 2015, 115, 26B-31B.	0.7	75
141	Novel Diabetes Drugs and the Cardiovascular Specialist. Journal of the American College of Cardiology, 2017, 69, 2646-2656.	1.2	75
142	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. JAMA Cardiology, 2020, 5, 757.	3.0	74
143	Risk Factors and Outcomes of Very Young Adults Who Experience Myocardial Infarction: The Partners YOUNG-MI Registry. American Journal of Medicine, 2020, 133, 605-612.e1.	0.6	73
144	Comparison of aortic dissection in patients with and without Marfan's syndrome (results from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	72

#	Article	IF	Citations
145	Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. American Heart Journal, 2012, 163, 1002-1010.	1.2	72
146	Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly InhibitÂCirculating Neprilysin Activity inÂHeartÂFailure. JACC: Heart Failure, 2015, 3, 629-636.	1.9	72
147	Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages inÂthe Community. JACC: Heart Failure, 2016, 4, 808-815.	1.9	72
148	Association of atrial fibrillation and amino-terminal proâ€"brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. American Heart Journal, 2007, 153, 90-97.	1.2	71
149	Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. European Heart Journal, 2008, 29, 1011-1018.	1.0	71
150	Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). American Heart Journal, 2018, 199, 130-136.	1.2	71
151	Heart Failure Outcomes and Benefits of NT-proBNP-Guided Management in the Elderly: Results From the Prospective, Randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Journal of Cardiac Failure, 2012, 18, 626-634.	0.7	70
152	Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. European Journal of Heart Failure, 2013, 15, 342-351.	2.9	70
153	Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, FluidÂHomeostasis, Inflammation, and Renal Injury. JACC: Heart Failure, 2015, 3, 30-39.	1.9	70
154	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. Journal of the American College of Cardiology, 2019, 73, 2439-2450.	1.2	69
155	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2021, 23, 1610-1632.	2.9	69
156	Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Critical Care, 2006, 10, R37.	2.5	68
157	Î²-Trace Protein and Cystatin C as Predictors of Long-Term Outcomes in Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2011, 57, 849-858.	1.2	66
158	Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening. Journal of the American Heart Association, 2013, 2, e000399.	1.6	66
159	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. European Journal of Heart Failure, 2020, 22, 1357-1365.	2.9	66
160	The Differential Diagnosis of an Elevated Amino-Terminal Proâ€"B-Type Natriuretic Peptide Level. American Journal of Cardiology, 2008, 101, S43-S48.	0.7	65
161	NT-proBNP Goal Achievement IsÂAssociated With Significant ReverseÂRemodeling and Improved Clinical Outcomes in HFrEF. JACC: Heart Failure, 2019, 7, 158-168.	1.9	65
162	Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation. Journal of Clinical Oncology, 2019, 37, 2778-2785.	0.8	64

#	Article	IF	Citations
163	A validated clinical and biochemical score for the diagnosis of acute heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. American Heart Journal, 2006, 151, 48-54.	1.2	63
164	Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein as Predictors of Sudden Cardiac Death Among Women. Circulation, 2009, 119, 2868-2876.	1.6	62
165	Sex Differences in Heart Failure. Journal of Cardiac Failure, 2022, 28, 477-498.	0.7	62
166	ST2: a novel biomarker for heart failure. Expert Review of Molecular Diagnostics, 2010, 10, 459-464.	1.5	60
167	Prognostic Usefulness of Insulin-Like Growth Factor-Binding Protein 7 in Heart Failure With Reduced Ejection Fraction: A Novel Biomarker of Myocardial Diastolic Function?. American Journal of Cardiology, 2014, 114, 1543-1549.	0.7	60
168	Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. American Heart Journal, 2010, 159, 532-538.e1.	1.2	58
169	Insulin-Like Growth Factorâ€"Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity inÂHeart Failure With Preserved EjectionÂFraction. JACC: Heart Failure, 2016, 4, 860-869.	1.9	58
170	Modulation of <scp>IL</scp>â€33/<scp>ST</scp>2 system in postinfarction heart failure: correlation with cardiac remodelling markers. European Journal of Clinical Investigation, 2014, 44, 643-651.	1.7	57
171	Medication dosing for heart failure with reduced ejection fraction â€" opportunities and challenges. European Journal of Heart Failure, 2019, 21, 286-296.	2.9	57
172	The role of natriuretic peptide testing in guiding chronic heart failure management: Review of available data and recommendations for use. Archives of Cardiovascular Diseases, 2012, 105, 40-50.	0.7	56
173	Copeptin Does Not Add Diagnostic Information to High-Sensitivity Troponin T in Low- to Intermediate-Risk Patients with Acute Chest Pain: Results from the Rule Out Myocardial Infarction by Computed Tomography (ROMICAT) Study. Clinical Chemistry, 2011, 57, 1137-1145.	1.5	55
174	A Clinical and Biomarker Scoring System to Predict the Presence of Obstructive Coronary Artery Disease. Journal of the American College of Cardiology, 2017, 69, 1147-1156.	1.2	55
175	Prognostic Importance of NT-proBNP andÂEffect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 78, 1321-1332.	1.2	55
176	Improving the Diagnosis of Acute Heart Failure Using a Validated Prediction Model. Journal of the American College of Cardiology, 2009, 54, 1515-1521.	1.2	54
177	Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. American Heart Journal, 2012, 164, 793-799.e1.	1.2	54
178	When Cardiac Failure, Kidney Dysfunction, and Kidney Injury Intersect in Acute Conditions. Critical Care Medicine, 2014, 42, 2109-2117.	0.4	54
179	Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clinical Research in Cardiology, 2015, 104, 491-499.	1.5	54
180	Associations of Circulating Growth Differentiation Factor-15 and ST2 Concentrations With Subclinical Vascular Brain Injury and Incident Stroke. Stroke, 2015, 46, 2568-2575.	1.0	54

#	Article	IF	Citations
181	Natriuretic Peptide Response and Outcomes in Chronic HeartÂFailure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 1205-1217.	1.2	54
182	Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 1455-1465.	1.2	54
183	Hyponatremia, Natriuretic Peptides, and Outcomes in Acutely Decompensated Heart Failure. Circulation: Heart Failure, 2010, 3, 354-361.	1.6	53
184	Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. Atherosclerosis, 2016, 248, 245-251.	0.4	53
185	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. JACC: Heart Failure, 2020, 8, 347-358.	1.9	53
186	Independent and incremental prognostic value of multimarker testing in acute dyspnea: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clinica Chimica Acta, 2008, 392, 41-45.	0.5	52
187	Pulmonary Production of Soluble ST2 in Heart Failure. Circulation: Heart Failure, 2018, 11, e005488.	1.6	52
188	Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome*. Critical Care Medicine, 2007, 35, 2484-2490.	0.4	51
189	Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea. American Journal of Medicine, 2016, 129, 96-104.e7.	0.6	51
190	Type 2 Myocardial Infarctionâ€"Diagnosis, Prognosis, and Treatment. JAMA - Journal of the American Medical Association, 2018, 320, 433.	3.8	51
191	Mechanistic Biomarkers Informative ofÂBoth Cancer and Cardiovascular Disease. Journal of the American College of Cardiology, 2020, 75, 2726-2737.	1.2	51
192	Understanding Amino-Terminal Proâ€"B-Type Natriuretic Peptide in Obesity. American Journal of Cardiology, 2008, 101, S89-S94.	0.7	50
193	The effects of optimism and gratitude on adherence, functioning and mental health following an acute coronary syndrome. General Hospital Psychiatry, 2016, 43, 17-22.	1.2	50
194	Circulating Proneurotensin Concentrations and Cardiovascular Disease Events in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1692-1697.	1.1	50
195	Prevalent and Incident Heart Failure inÂCardiovascular Outcome Trials of Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 2018, 71, 1379-1390.	1.2	50
196	Effects of Canagliflozin on Amino-Terminal Proâ€"B-Type NatriureticÂPeptide. Journal of the American College of Cardiology, 2020, 76, 2076-2085.	1.2	50
197	Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction. Journal of the American College of Cardiology, 2021, 77, 848-857.	1.2	50
198	Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling. Journal of Cardiovascular Translational Research, 2014, 7, 250-261.	1.1	49

#	Article	IF	Citations
199	Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. European Journal of Heart Failure, 2015, 17, 1114-1123.	2.9	49
200	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. Circulation, 2019, 139, 1458-1460.	1.6	49
201	Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults. Journal of the American College of Cardiology, 2020, 75, 1003-1013.	1.2	49
202	Omics phenotyping in heart failure: the next frontier. European Heart Journal, 2020, 41, 3477-3484.	1.0	48
203	Importance of Biomarkers for Long-Term Mortality Prediction in Acutely Dyspneic Patients. Clinical Chemistry, 2010, 56, 1814-1821.	1.5	47
204	Prognostic and Diagnostic Value of Plasma Soluble Suppression of Tumorigenicity-2 Concentrations in Acute Respiratory Distress Syndrome. Critical Care Medicine, 2013, 41, 2521-2531.	0.4	47
205	The Dynamics of Cardiovascular Biomarkers in non-Elite Marathon Runners. Journal of Cardiovascular Translational Research, 2017, 10, 206-208.	1.1	47
206	Multimodality Imaging in Evaluation of Cardiovascular Complications in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 1345-1357.	1.2	47
207	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2021, 9, 127-136.	1.9	47
208	Acute Aortic Dissection Presenting With Congestive Heart Failure: Results From the International Registry of Acute Aortic Dissection. Journal of the American College of Cardiology, 2005, 46, 733-735.	1.2	46
209	Soluble ST2 Plasma Concentrations Predict 1-Year Mortality in Acutely Dyspneic Emergency Department Patients With Pulmonary Disease. American Journal of Clinical Pathology, 2008, 130, 578-584.	0.4	46
210	Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study. Heart Rhythm, 2014, 11, 2167-2175.	0.3	46
211	High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD. JACC: Cardiovascular Imaging, 2019, 12, 1047-1055.	2.3	46
212	Psychiatric and Psychological Interventions for Depression in Patients With Heart Disease: A Scoping Review. Journal of the American Heart Association, 2020, 9, e018686.	1.6	46
213	Delirium in the Cardiac Intensive Care Unit. Journal of the American Heart Association, 2018, 7, .	1.6	44
214	Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine, 2020, 26, 100504.	3.2	44
215	Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient—part 1. Acute Cardiac Care, 2009, 11, 3-42.	0.2	43
216	Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC Heart Failure, 2019, 6, 784-792.	1.4	43

#	Article	IF	Citations
217	Usefulness of a Positive Psychology-Motivational Interviewing Intervention to Promote Positive Affect and Physical Activity After an Acute Coronary Syndrome. American Journal of Cardiology, 2019, 123, 1906-1914.	0.7	43
218	Soluble ST2 predicts elevated SBP in the community. Journal of Hypertension, 2013, 31, 1431-1436.	0.3	42
219	hs-Troponin I Followed by CT Angiography Improves Acute Coronary Syndrome Risk Stratification Accuracy and Work-Up in Acute Chest Pain Patients. JACC: Cardiovascular Imaging, 2015, 8, 1272-1281.	2.3	42
220	Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials. Circulation: Heart Failure, 2016, 9, .	1.6	42
221	Association of the New Peer Group–Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. JAMA Network Open, 2019, 2, e192987.	2.8	42
222	Soluble ST2 Is a Marker for Acute Cardiac Allograft Rejection. Annals of Thoracic Surgery, 2011, 92, 2118-2124.	0.7	41
223	Comparison of Risk Prediction With the CKD-EPI and MDRD Equations in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2013, 19, 583-591.	0.7	41
224	Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. Clinical Chemistry, 2017, 63, 211-222.	1.5	41
225	Biomarkers in ACS and Heart Failure: Should Men and Women Be Interpreted Differently?. Clinical Chemistry, 2014, 60, 35-43.	1.5	40
226	Outcomes of Patients With Acute Decompensated Heart Failure Managed by Cardiologists Versus Noncardiologists. American Journal of Cardiology, 2015, 115, 466-471.	0.7	40
227	IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circulation: Heart Failure, 2018, 11, e005133.	1.6	40
228	Neither Race nor Gender Influences the Usefulness of Amino-Terminal Pro-Brain Natriuretic Peptide Testing in Dyspneic Subjects: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Substudy. Journal of Cardiac Failure, 2006, 12, 452-457.	0.7	39
229	Characterization and Prediction of Natriuretic Peptide "Nonresponse" During Heart Failure Management: Results From the Pro<scp>BNP</scp> Outpatient Tailored Chronic Heart Failure (<scp>PROTECT</scp>) and the <scp>NT</scp>–pro<scp>BNP</scp>–Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (<scp>BATTLESCARRED</scp>) Study. Congestive Heart Failure, 2013, 19, 135-142.	2.0	39
230	Biomarkers in stable coronary artery disease. American Heart Journal, 2018, 196, 82-96.	1.2	39
231	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. European Heart Journal, 2022, 43, 3435-3446.	1.0	39
232	Amino-Terminal Pro–Brain Natriuretic Peptide, Brain Natriuretic Peptide, and Troponin T for Prediction of Mortality in Acute Heart Failure. Clinical Chemistry, 2007, 53, 412-420.	1.5	38
233	Amino-Terminal Pro–B-Type Natriuretic Peptide Testing and Prognosis in Patients with Acute Dyspnea, Including Those with Acute Heart Failure. American Journal of Cardiology, 2008, 101, S49-S55.	0.7	38
234	Society of Chest Pain Centers Recommendations for the Evaluation and Management of the Observation Stay Acute Heart Failure Patient. Critical Pathways in Cardiology, 2008, 7, 83-121.	0.2	38

#	Article	IF	Citations
235	The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Review of Cardiovascular Therapy, 2015, 13, 1017-1030.	0.6	37
236	Importance and Interpretation of Intermediate (Gray Zone) Amino-Terminal Proâ€"B-Type Natriuretic Peptide Concentrations. American Journal of Cardiology, 2008, 101, S39-S42.	0.7	36
237	The evolution of the natriuretic peptides â€" Current applications in human and animal medicine. Journal of Veterinary Cardiology, 2009, 11, S9-S21.	0.3	36
238	Natriuretic Peptides in Heart Failure and Acute Coronary Syndrome. Clinics in Laboratory Medicine, 2014, 34, 43-58.	0.7	36
239	Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain. Journal of the American College of Cardiology, 2019, 73, 251-260.	1.2	36
240	Clinical factors related to morbidity and mortality in highâ€risk heart failure patients: the GUIDEâ€‘IT predictive model and risk score. European Journal of Heart Failure, 2019, 21, 770-778.	2.9	36
241	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With HeartÂFailure and Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2022, 79, 1129-1137.	1.2	36
242	Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure. Clinica Chimica Acta, 2007, 381, 145-150.	0.5	35
243	Red blood cell distribution width predicts new-onset anemia in heart failure patients. International Journal of Cardiology, 2012, 160, 196-200.	0.8	35
244	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. Journal of Cardiac Failure, 2017, 23, 20-28.	0.7	35
245	Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378.	1.2	35
246	Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. Journal of the American College of Cardiology, 2022, 79, 617-628.	1.2	35
247	Amino-Terminal Pro-Brain Natriuretic Peptide for the Diagnosis of Acute Heart Failure in Patients With Previous Obstructive Airway Disease. Annals of Emergency Medicine, 2006, 48, 66-74.	0.3	34
248	Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study. Clinical Chemistry, 2017, 63, 386-393.	1.5	34
249	Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Critical Care, 2012, 16, R135.	2.5	33
250	The Many Faces of TypeÂ2ÂMyocardialÂInfarction. Journal of the American College of Cardiology, 2017, 70, 1569-1572.	1.2	33
251	A clinical, proteomics, and artificial intelligenceâ€driven model to predict acute kidney injury in patients undergoing coronary angiography. Clinical Cardiology, 2019, 42, 292-298.	0.7	33
252	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4455-4464.	1.0	33

#	Article	IF	Citations
253	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 2022, 15, 1.	6.9	33
254	Natriuretic Peptides as Biomarkers in Heart Failure. Journal of Investigative Medicine, 2013, 61, 950-955.	0.7	32
255	Evidence of Uncoupling between Renal Dysfunction and Injury in Cardiorenal Syndrome: Insights from the BIONICS Study. PLoS ONE, 2014, 9, e112313.	1.1	32
256	Soluble ST2 and Galectin-3 in Heart Failure. Clinics in Laboratory Medicine, 2014, 34, 87-97.	0.7	32
257	Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American Heart Journal, 2015, 169, 404-411.e3.	1.2	32
258	MicroRNAs Associated With Reverse Left Ventricular Remodeling in Humans Identify Pathways of Heart Failure Progression. Circulation: Heart Failure, 2018, 11, e004278.	1.6	32
259	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International Journal of Cardiology, 2019, 277, 166-172.	0.8	32
260	Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes. ESC Heart Failure, 2021, 8, 2741-2754.	1.4	32
261	Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure. Revista Espanola De Cardiologia (English Ed), 2010, 63, 1171-1178.	0.4	31
262	A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department. American Heart Journal, 2011, 162, 276-282.e1.	1.2	31
263	Surfing the Biomarker Tsunami at JACC: Heart Failure. JACC: Heart Failure, 2013, 1, 213-215.	1.9	31
264	ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. Journal of Cardiac Failure, 2015, 21, 355-361.	0.7	31
265	Natriuretic Peptide Testing for Predicting Adverse Events Following Heart Failure Hospitalization. Congestive Heart Failure, 2012, 18, S9-S13.	2.0	30
266	Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure. Journal of Cardiovascular Translational Research, 2015, 8, 164-172.	1.1	30
267	The Positive Emotions after Acute Coronary Events behavioral health intervention: Design, rationale, and preliminary feasibility of a factorial design study. Clinical Trials, 2017, 14, 128-139.	0.7	30
268	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. JACC: Heart Failure, 2017, 5, 735-742.	1.9	30
269	Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the <scp>EMPEROR</scp>‐Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538.	2.9	30
270	Lipoprotein(a) and Cardiovascular Diseases. JAMA - Journal of the American Medical Association, 2021, 326, 352.	3.8	30

#	Article	IF	Citations
271	Recovery of Left Ventricular Systolic Function and Clinical Outcomes in Young Adults With Myocardial Infarction. Journal of the American College of Cardiology, 2020, 75, 2804-2815.	1.2	30
272	Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. American Journal of Cardiology, 2004, 93, 843-847.	0.7	29
273	Biomarcadores en la insuficiencia cardiaca aguda. Revista Espanola De Cardiologia, 2015, 68, 514-525.	0.6	29
274	The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study. Current Heart Failure Reports, 2018, 15, 37-43.	1.3	29
275	A call to action for new global approaches to cardiovascular disease drug solutions. European Heart Journal, 2021, 42, 1464-1475.	1.0	29
276	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 35-45.	5.5	29
277	Cardiac remodellingÂâ€"ÂPart 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 927-943.	2.9	29
278	Impact of Statin Use on Exercise-Induced Cardiac Troponin Elevations. American Journal of Cardiology, 2014, 114, 624-628.	0.7	28
279	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. European Journal of Preventive Cardiology, 2019, 26, 1751-1759.	0.8	28
280	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. Circulation: Heart Failure, 2020, 13, e006946.	1.6	28
281	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation, 2021, 144, 180-182.	1.6	28
282	Elevation in serum troponin I predicts the benefit of tirofiban. Journal of Thrombosis and Thrombolysis, 2001, 11, 211-215.	1.0	27
283	Natriuretic Peptides in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 453-470.	1.0	27
284	Plasma Concentrations of Soluble Suppression of Tumorigenicity-2 and Interleukin-6 Are Predictive of Successful Liberation From Mechanical Ventilation in Patients With the Acute Respiratory Distress Syndrome*. Critical Care Medicine, 2016, 44, 1735-1743.	0.4	27
285	NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. International Journal of Cardiology, 2018, 271, 324-330.	0.8	27
286	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. Diabetes Care, 2020, 43, 1843-1850.	4.3	27
287	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. JACC: Heart Failure, 2021, 9, 137-145.	1.9	27
288	Association Between Angiotensin Receptorâ€"Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2021, 14, e008410.	1.6	27

#	Article	IF	Citations
289	Practical outpatient management of worsening chronic heart failure. European Journal of Heart Failure, 2022, 24, 750-761.	2.9	27
290	Effects of tirofiban plus heparin versus heparin alone on troponin i levels in patients with acute coronary syndromes. American Journal of Cardiology, 2000, 86, 713-717.	0.7	26
291	Usefulness of Natriuretic Peptide Testing for Long-Term Risk Assessment Following Acute Ischemic Stroke. American Journal of Cardiology, 2009, 104, 287-291.	0.7	26
292	Natriuretic Peptide-Guided Management of Acutely Destabilized Heart Failure. Critical Pathways in Cardiology, 2009, 8, 146-150.	0.2	26
293	Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study. International Journal of Cardiology, 2016, 204, 242-247.	0.8	26
294	Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness. Value in Health, 2016, 19, 185-191.	0.1	26
295	Clinical implementation of an emergency department coronary computed tomographic angiography protocol for triage of patients with suspected acute coronary syndrome. European Radiology, 2017, 27, 2784-2793.	2.3	26
296	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. European Heart Journal, 2018, 39, 2793-2799.	1.0	26
297	A Meta-Analysis of Genome-Wide Association Studies of Growth Differentiation Factor-15 Concentration in Blood. Frontiers in Genetics, 2018, 9, 97.	1.1	26
298	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Cardiology, 2019, 124, S20-S27.	0.7	26
299	Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death. Journal of the American College of Cardiology, 2019, 73, 2135-2145.	1.2	26
300	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T. European Journal of Heart Failure, 2020, 22, 2078-2088.	2.9	26
301	Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure.. Cleveland Clinic Journal of Medicine, 2006, 73, 149-152.	0.6	26
302	Reference Interval Evaluation of High-Sensitivity Troponin T and N-Terminal B-Type Natriuretic Peptide in Vietnam and the US: The North South East West Trial. Clinical Chemistry, 2014, 60, 758-764.	1.5	25
303	Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. Clinical Chemistry and Laboratory Medicine, 2015, 53, 613-21.	1.4	25
304	Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome. Critical Care Medicine, 2017, 45, e666-e673.	0.4	25
305	Endothelial heparan sulfate is necessary but not sufficient for control of vascular smooth muscle cell growth. , 2000, 184, 93-100.		24
306	Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. American Journal of Cardiology, 2003, 91, 457-461.	0.7	24

#	Article	IF	Citations
307	Peripheral arterial disease, acute coronary syndromes, and early invasive management: The TACTICS TIMI 18 trial. Clinical Cardiology, 2005, 28, 238-242.	0.7	24
308	Association between troponin T and impaired left ventricular relaxation in patients with acute decompensated heart failure with preserved systolic function. European Journal of Echocardiography, 2009, 10, 765-768.	2.3	24
309	Biomarkers of Cardiovascular Stress and Subclinical Atherosclerosis in the Community. Clinical Chemistry, 2014, 60, 1402-1408.	1.5	24
310	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. International Journal of Cardiology, 2019, 293, 137-142.	0.8	24
311	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 2019, 21, 386-388.	2.9	24
312	A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. Global Heart, 2019, 14, 215.	0.9	24
313	Usefulness of Aminoterminal Pro-Brain Natriuretic Peptide Testing for the Diagnostic and Prognostic Evaluation of Dyspneic Patients With Diabetes Mellitus Seen in the Emergency Department (from the) Tj ETQq1 1 0.784314 rgBT /Over	0.7	23
314	Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syndrome diagnosis in emergency department patients with chest pain: From the â€œRule Out Myocardial Infarction Using Computer Assisted Tomographyâ€•(ROMICAT) trial. American Heart Journal, 2012, 163, 972-979.e1.	1.2	23
315	Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. American Heart Journal, 2015, 169, 572-578.e1.	1.2	23
316	The Evolving Medical Complexity of the Modern Cardiac Intensive Care Unit âˆ—. Journal of the American College of Cardiology, 2017, 69, 2008-2010.	1.2	23
317	Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in) Tj ETQq1 1 0.784314 rgBT 2Overloc	1.2	23
318	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186.	2.9	23
319	Novel Trial Design: CHIEF-HF. Circulation: Heart Failure, 2021, 14, e007767.	1.6	23
320	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	2.9	23
321	Natriuretic Peptide Testing in Clinical Medicine. Cardiology in Review, 2008, 16, 240-249.	0.6	22
322	Biomarkers in the Management of Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 519-531.	0.4	22
323	ST2 in Pulmonary Disease. American Journal of Cardiology, 2015, 115, 44B-47B.	0.7	22
324	Type 2 myocardial infarction due to supplyâ€"demand mismatch. Trends in Cardiovascular Medicine, 2017, 27, 408-417.	2.3	22

#	Article	IF	Citations
325	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118.	1.6	22
326	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. Journal of Cardiac Failure, 2019, 25, 78-86.	0.7	22
327	Cardiac remodellingâ€"Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958.	2.9	22
328	Natriuretic Peptides in Heart Failure. Clinical Chemistry, 2014, 60, 1040-1046.	1.5	21
329	Biomarkers in Acute Heart Failure. Revista Espanola De Cardiologia (English Ed), 2015, 68, 514-525.	0.4	21
330	Sexâ€based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. European Journal of Heart Failure, 2020, 22, 2018-2025.	2.9	21
331	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. Journal of the American College of Cardiology, 2022, 79, 432-444.	1.2	21
332	Biomarkerâ€driven prognostic models in chronic heart failure with preserved ejection fraction: the <scp>EMPEROR</scp>â€"Preserved trial. European Journal of Heart Failure, 2022, 24, 1869-1878.	2.9	21
333	Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. , 1999, 7, 259-264.		20
334	Use of the Patient Health Questionnaire-9 and a Detailed Suicide Evaluation in Determining Imminent Suicidality in Distressed Patients With Cardiac Disease. Psychosomatics, 2015, 56, 181-189.	2.5	20
335	Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure. Biomarkers in Medicine, 2015, 9, 433-441.	0.6	20
336	Economic and Quality-of-Life Outcomes of Natriuretic Peptideâ€"Guided Therapy for HeartÂFailure. Journal of the American College of Cardiology, 2018, 72, 2551-2562.	1.2	20
337	Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 3-11.	1.4	20
338	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in HeartÂFailure and Reduced EjectionÂFraction. JACC: Heart Failure, 2021, 9, 42-51.	1.9	20
339	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. Clinical Research in Cardiology, 2021, 110, 1280-1291.	1.5	20
340	NT-proBNP for Risk Prediction in HeartÂFailure. JACC: Heart Failure, 2021, 9, 653-663.	1.9	20
341	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF. JACC: Heart Failure, 2022, 10, 266-275.	1.9	20
342	Prognostic Implications of N-Terminal Proâ€"B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. JACC: Heart Failure, 2022, 10, 512-524.	1.9	20

#	Article	IF	Citations
343	Use of biomarkers to guide outpatient therapy of heart failure. Current Opinion in Cardiology, 2012, 27, 661-668.	0.8	19
344	Usefulness of Combining Galectin-3 and BIVA Assessments in Predicting Short- and Long-Term Events in Patients Admitted for Acute Heart Failure. BioMed Research International, 2014, 2014, 1-10.	0.9	19
345	Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. IJC Metabolic & Endocrine, 2014, 5, 11-18.	0.5	19
346	The Importance of Worsening HeartÂFailure in Ambulatory Patients. JACC: Heart Failure, 2016, 4, 749-755.	1.9	19
347	Systematic Evaluation of Endothelin 1 Measurement Relative to Traditional and Modern Biomarkers for Clinical Assessment and Prognosis in Patients With Chronic Systolic Heart Failure. American Journal of Clinical Pathology, 2017, 147, 461-472.	0.4	19
348	Mind the Gap: Current Challenges and Future State of Heart Failure Care. Canadian Journal of Cardiology, 2017, 33, 1434-1449.	0.8	19
349	High-Sensitivity Cardiac Troponin I as a Gatekeeper for Coronary Computed Tomography Angiography and Stress Testing in Patients with Acute Chest Pain. Clinical Chemistry, 2017, 63, 1724-1733.	1.5	19
350	Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. International Journal of Cardiology, 2018, 254, 215-221.	0.8	19
351	Echocardiographic assessment of insulinâ€like growth factor binding proteinâ€7 and early identification of acute heart failure. ESC Heart Failure, 2020, 7, 1664-1675.	1.4	19
352	Reverse Cardiac Remodeling and ARNI Therapy. Current Heart Failure Reports, 2021, 18, 71-83.	1.3	19
353	A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings. Journal of the American College of Cardiology, 2021, 77, 1357-1367.	1.2	19
354	A Clinical and Biochemical Critical Pathway for the Evaluation of Patients With Suspected Acute Congestive Heart Failure. Critical Pathways in Cardiology, 2004, 3, 171-176.	0.2	19
355	Documento de consenso de expertos. Tercera definiciÃ³n universal del infarto de miocardio. Revista Espanola De Cardiologia, 2013, 66, 132.e1-132.e15.	0.6	18
356	A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload. Journal of Cardiac Failure, 2018, 24, 773-782.	0.7	18
357	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. Circulation: Heart Failure, 2020, 13, e007829.	1.6	18
358	Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes. Journal of the American College of Cardiology, 2021, 77, 1487-1499.	1.2	18
359	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. Circulation, 2021, 144, 159-169.	1.6	18
360	Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. BMJ, The, 0, , e068424.	3.0	18

#	Article	IF	Citations
361	Predicting a late positive serum troponin in initially troponin-negative patients with non–ST-elevation acute coronary syndrome: Clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. American Heart Journal, 2006, 151, 360-366.	1.2	17
362	Amino-Terminal Pro–B-Type Natriuretic Peptide Testing for Inpatient Monitoring and Treatment Guidance of Acute Destabilized Heart Failure. American Journal of Cardiology, 2008, 101, S67-S71.	0.7	17
363	Correlation of concentrations of high-sensitivity troponin T and high-sensitivity C-reactive protein with plaque progression as measured by CT coronary angiography. Journal of Cardiovascular Computed Tomography, 2014, 8, 452-458.	0.7	17
364	Cystatin C–based <scp>CKD–EPI</scp> Equations and N–Terminal Pro–B–Type Natriuretic Peptide for Predicting Outcomes in Acutely Decompensated Heart Failure. Clinical Cardiology, 2015, 38, 106-113.	0.7	17
365	Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure. Clinica Chimica Acta, 2015, 445, 73-78.	0.5	17
366	Comparison of Risk Prediction With the <scp>CKD–EPI</scp> and <scp>MDRD</scp> Equations in Non–<scp>ST</scp>–Segment Elevation Acute Coronary Syndrome. Clinical Cardiology, 2016, 39, 507-515.	0.7	17
367	New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis. Biomarkers, 2010, 15, 307-314.	0.9	16
368	Natriuretic Peptides, Ejection Fraction, and Prognosis. Journal of the American College of Cardiology, 2013, 61, 1507-1509.	1.2	16
369	The Potential Role of Natriuretic Peptide–Guided Management for Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2015, 21, 233-239.	0.7	16
370	Highly sensitive troponin and coronary computed tomography angiography in the evaluation of suspected acute coronary syndrome in the emergency department. European Heart Journal, 2016, 37, 2397-2405.	1.0	16
371	N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives. European Journal of Preventive Cardiology, 2016, 23, 366-376.	0.8	16
372	Evaluating Chest Pain in the Emergency Department. Journal of the American College of Cardiology, 2018, 71, 617-619.	1.2	16
373	Type 2 Myocardial Infarction and the Hospital Readmission Reduction Program. Journal of the American College of Cardiology, 2018, 72, 1166-1170.	1.2	16
374	Trivializing an Elevated Troponin. Journal of the American College of Cardiology, 2019, 73, 10-12.	1.2	16
375	Feasibility and preliminary efficacy of a positive psychology-based intervention to promote health behaviors in heart failure: The REACH for Health study. Journal of Psychosomatic Research, 2020, 139, 110285.	1.2	16
376	Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007440.	0.9	16
377	Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST–segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. American Heart Journal, 2003, 146, 764-774.	1.2	15
378	Use of Biomarkers to "Guide" Care in Chronic Heart Failure: What Have We Learned (So Far)?. Journal of Cardiac Failure, 2011, 17, 622-625.	0.7	15

#	Article	IF	Citations
379	Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers, 2013, 18, 250-256.	0.9	15
380	Standardized Definitions for EvaluationÂofÂHeart Failure Therapies: Scientific Expert Panel From the HeartÂFailure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	1.9	15
381	Finding a Needle in a Haystack. JACC Basic To Translational Science, 2020, 5, 1043-1053.	1.9	15
382	Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Failure, 2020, 7, 559-566.	1.4	15
383	Downstream Cascades of Care FollowingÂHigh-Sensitivity Troponin TestÂImplementation. Journal of the American College of Cardiology, 2021, 77, 3171-3179.	1.2	15
384	Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). American Journal of Cardiology, 2021, 148, 146-150.	0.7	15
385	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. Current Diabetes Reports, 2021, 21, 41.	1.7	15
386	Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2022, 10, 119-128.	1.9	15
387	Circulating levels and prognostic cutâ€offs of sST2, hsâ€cTnT, and NTâ€proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	1.4	15
388	Found in Translation. Journal of the American College of Cardiology, 2010, 55, 251-253.	1.2	14
389	Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study. Journal of Cardiac Failure, 2015, 21, 9-15.	0.7	14
390	Racial Differences in Serial NT-proBNP Levels in Heart Failure Management. Circulation, 2020, 142, 1018-1020.	1.6	14
391	Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. Diabetes Care, 2021, 44, 210-216.	4.3	14
392	Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. Circulation, 2021, 143, 2316-2318.	1.6	14
393	Combination of D-Dimer and Amino-Terminal Pro-B-Type Natriuretic Peptide Testing for the Evaluation of Dyspneic Patients With and Without Acute Pulmonary Embolism. Archives of Pathology and Laboratory Medicine, 2006, 130, 1326-1329.	1.2	14
394	Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain. JACC: Cardiovascular Imaging, 2022, 15, 1427-1438.	2.3	14
395	Natriuretic Peptide Guided Heart Failure Management. Current Clinical Pharmacology, 2009, 4, 87-94.	0.2	13
396	What to Expect When Measuring High-Sensitivity Troponin. Journal of the American College of Cardiology, 2015, 65, 1665-1667.	1.2	13

#	Article	IF	Citations
397	Design and baseline data from the Gratitude Research in Acute Coronary Events (GRACE) study. Contemporary Clinical Trials, 2015, 44, 11-19.	0.8	13
398	Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapyâ€"The BIOCRT Study. Canadian Journal of Cardiology, 2016, 32, 1478-1484.	0.8	13
399	Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. European Journal of Clinical Investigation, 2018, 48, e12907.	1.7	13
400	Clinical Profile of Acute Myocardial Infarction Patients Included in the Hospital Readmissions Reduction Program. Journal of the American Heart Association, 2018, 7, e009339.	1.6	13
401	A clinical and proteomics approach to predict the presence of obstructive peripheral arterial disease: From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. Clinical Cardiology, 2018, 41, 903-909.	0.7	13
402	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. Diabetes, Obesity and Metabolism, 2020, 22, 1243-1262.	2.2	13
403	Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea. JACC: Heart Failure, 2020, 8, 415-422.	1.9	13
404	Combined Use of Amino Terminal-Pro-Brain Natriuretic Peptide Levels and QRS Duration to Predict Left Ventricular Systolic Dysfunction in Patients With Dyspnea. American Journal of Cardiology, 2005, 96, 263-266.	0.7	12
405	When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'?. European Heart Journal, 2007, 28, 2960-2961.	1.0	12
406	Importance of Rigorous Evaluation in Comparative Biomarker Studies. Journal of the American College of Cardiology, 2014, 63, 167-169.	1.2	12
407	Circulating Concentrations of Orexin A Predict LeftÂVentricular Myocardial Remodeling. Journal of the American College of Cardiology, 2016, 68, 2238-2240.	1.2	12
408	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. Revista Espanola De Cardiologia (English Ed), 2017, 70, 924-932.	0.4	12
409	Strain Echocardiography. Journal of the American College of Cardiology, 2017, 70, 955-957.	1.2	12
410	Singleâ€Molecule Counting of Highâ€Sensitivity Troponin I in Patients Referred for Diagnostic Angiography: Results From the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular) Tj ETQq0 0 0 rgBT /Overlock 210 Tf 50	1.6	12
411	Natriuretic Peptideâ€"Guided Heart Failure Therapy After the GUIDE-IT Study. Circulation, 2018, 137, 2101-2103.	1.6	12
412	Cause of Death in Patients With AcuteÂHeartÂFailure. JACC: Heart Failure, 2020, 8, 999-1008.	1.9	12
413	Derivation and External Validation of a Highâ€Sensitivity Cardiac Troponinâ€"Based Proteomic Model to Predict the Presence of Obstructive Coronary Artery Disease. Journal of the American Heart Association, 2020, 9, e017221.	1.6	12
414	The Challenges of NT-proBNP Testing inÂHFpEF. JACC: Heart Failure, 2020, 8, 382-385.	1.9	12

#	Article	IF	Citations
415	Pre-admission NT-proBNP improves diagnostic yield and risk stratification â€" the NT-proBNP for EValuation of dyspnoeic patients in the Emergency Room and hospital (BNP4EVER) study. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 99-108.	0.4	11
416	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. Journal of Thrombosis and Thrombolysis, 2017, 44, 457-465.	1.0	11
417	Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. International Journal of Cardiology, 2018, 273, 136-140.	0.8	11
418	Exercise-induced Changes in Soluble ST2 Concentrations in Marathon Runners. Medicine and Science in Sports and Exercise, 2019, 51, 405-410.	0.2	11
419	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC: Heart Failure, 2022, 10, 1-11.	1.9	11
420	Natriuretic Peptide Testing for Heart Failure Therapy Guidance in the Inpatient and Outpatient Setting. American Journal of Therapeutics, 2009, 16, 171-177.	0.5	10
421	The Prognostic Value of Plasma Soluble ST2 in Hospitalized Chinese Patients with Heart Failure. PLoS ONE, 2014, 9, e110976.	1.1	10
422	Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. Europace, 2017, 19, 1848-1854.	0.7	10
423	Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Journal of Cardiac Failure, 2017, 23, 121-130.	0.7	10
424	The past, the present, and the future of natriuretic peptides in the diagnosis of heart failure. European Heart Journal Supplements, 2018, 20, G11-G20.	0.0	10
425	Proteomic Signatures During Treatment in Different Stages of Heart Failure. Circulation: Heart Failure, 2020, 13, e006794.	1.6	10
426	Pre-analytical considerations in biomarker research: focus on cardiovascular disease. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1747-1760.	1.4	10
427	The â€˜Peptide for Lifeâ€™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across <scp>Europe</scp>. European Journal of Heart Failure, 2021, 23, 1432-1436.	2.9	10
428	The Impact of Amino-Terminal Pro-Brain Natriuretic Peptide Testing on Hospital Length of Stay and Morbidity in Patients With Acute Decompensated Heart Failure. Archives of Pathology and Laboratory Medicine, 2007, 131, 473-476.	1.2	10
429	Using Biomarkers to â€œGuideâ€•Heart Failure Management. Cardiology in Review, 2013, 21, 127-134.	0.6	9
430	Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy: The BIOCRT study. International Journal of Cardiology, 2016, 205, 43-49.	0.8	9
431	Serial Echocardiographic Characteristics, Novel Biomarkers and Cachexia Development in Patients with Stable Chronic Heart Failure. Journal of Cardiovascular Translational Research, 2016, 9, 429-431.	1.1	9
432	Will Biomarkers Succeed as a Surrogate Endpoint in Heart Failure Trials?. JACC: Heart Failure, 2018, 6, 570-572.	1.9	9

#	Article	IF	Citations
433	Performance of a clinical/proteomic panel to predict obstructive peripheral artery disease in patients with and without diabetes mellitus. Open Heart, 2019, 6, e000955.	0.9	9
434	Cardiorenal status using amino-terminal pro–brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study. Heart Rhythm, 2019, 16, 928-935.	0.3	9
435	Blood kidney injury molecule–1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography–Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. American Heart Journal, 2019, 209, 36-46.	1.2	9
436	Evolution of amino-terminal Pro-B type natriuretic peptide testing in heart failure. Drug News and Perspectives, 2009, 22, 267.	1.9	9
437	Inflammatory Markers, Amino-Terminal Pro-Brain Natriuretic Peptide, and Mortality Risk in Dyspneic Patients. American Journal of Clinical Pathology, 2008, 130, 305-311.	0.4	8
438	Natriuretic Peptides in the Diagnosis and Management of Acute Heart Failure. Heart Failure Clinics, 2009, 5, 489-500.	1.0	8
439	Relative value of amino-terminal pro-B-type natriuretic peptide testing and radiographic standards for the diagnostic evaluation of heart failure in acutely dyspneic subjects. Biomarkers, 2010, 15, 175-182.	0.9	8
440	Critical research on biomarkers: what's new?. Intensive Care Medicine, 2013, 39, 1824-1828.	3.9	8
441	Acute Coronary Syndrome Antiplatelet Alternatives in Clopidogrel Allergy. Pharmacotherapy, 2014, 34, e152-6.	1.2	8
442	ST2 Predicts Mortality and Length of Stay in a Critically Ill Noncardiac Intensive Care Unit Population. American Journal of Clinical Pathology, 2016, 145, 203-210.	0.4	8
443	Plasma Glycoproteomic Study of Therapeutic Hypothermia Reveals Novel Markers Predicting Neurologic Outcome Post-cardiac Arrest. Translational Stroke Research, 2018, 9, 64-73.	2.3	8
444	Multiple biomarker panel to screen for severe aortic stenosis: results from the CASABLANCA study. Open Heart, 2018, 5, e000916.	0.9	8
445	Endothelin-1 Measurement in Patients Undergoing Diagnostic Coronary Angiography–Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. Clinical Chemistry, 2018, 64, 1617-1625.	1.5	8
446	Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1257-1265.	2.5	8
447	Analytical and clinical performance of the Ortho-Clinical Diagnostics VITROS® amino-terminal pro-B type natriuretic peptide assay. Clinica Chimica Acta, 2008, 387, 48-54.	0.5	7
448	The Role of Natriuretic Peptides: From the Emergency Department Throughout Hospitalization. Congestive Heart Failure, 2012, 18, S5-8.	2.0	7
449	B-Type Natriuretic Peptide Testing in the Era of Neprilysin Inhibition: Are the Winds of Change Blowing?. Clinical Chemistry, 2016, 62, 663-665.	1.5	7
450	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. Diabetes, Obesity and Metabolism, 2019, 21, 261-266.	2.2	7

#	Article	IF	Citations
451	Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy. Journal of Thoracic Disease, 2019, 11, 5362-5371.	0.6	7
452	Understanding the Mechanistic Benefit of HeartÂFailure Drugs Matters. Journal of the American College of Cardiology, 2020, 76, 2752-2754.	1.2	7
453	Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assayâ€™s Limit of Detection?. Clinical Chemistry, 2020, 66, 1146-1149.	1.5	7
454	Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. Clinical Cardiology, 2020, 43, 1209-1215.	0.7	7
455	Comparison of longitudinal change in sST2 vs BNP to predict major adverse cardiovascular events in asymptomatic patients in the community. Journal of Cellular and Molecular Medicine, 2020, 24, 6495-6499.	1.6	7
456	Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 447-455.	1.2	7
457	Gaining Efficiency in Clinical Trials With Cardiac Biomarkers. Journal of the American College of Cardiology, 2021, 77, 1922-1933.	1.2	7
458	Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes. Journal of the American College of Cardiology, 2021, 78, 1242-1253.	1.2	7
459	The Editor's Roundtable: B-Type Natriuretic Peptide. American Journal of Cardiology, 2008, 101, 1733-1740.	0.7	6
460	Erythropoietin in cardiovascular diseases: exploring new avenues. Clinical Science, 2008, 114, 289-291.	1.8	6
461	Beta-Trace Protein and Cystatin C as Predictors of Major Bleeding in Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation Journal, 2013, 77, 2088-2096.	0.7	6
462	Using Biomarkers to Guide Heart Failure Therapy. Clinical Chemistry, 2017, 63, 954-957.	1.5	6
463	Predicting newâ€onset HF in patients undergoing coronary or peripheral angiography: results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. ESC Heart Failure, 2018, 5, 240-248.	1.4	6
464	Incidence, Predictors, and Outcomes of Thrombotic Events in Hospitalized Patients With Viral Pneumonia. American Journal of Cardiology, 2021, 143, 164-165.	0.7	6
465	Differences in NTâ€proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e019712.	1.6	6
466	Economic Evaluation of an N-terminal Pro B-type Natriuretic Peptide-Supported Diagnostic Strategy Among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department. American Journal of Cardiology, 2021, 147, 61-69.	0.7	6
467	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy. PLoS ONE, 2021, 16, e0258622.	1.1	6
468	Cardiovascular benefit of SGLT2 inhibitors. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 142-155.	2.7	6

#	Article	IF	Citations
469	Relation of High-Sensitivity Cardiac Troponin I and Obstructive Coronary Artery Disease in Patients Without Acute Myocardial Infarction. American Journal of Cardiology, 2022, 173, 16-24.	0.7	6
470	Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography. American Heart Journal, 2022, 252, 51-59.	1.2	6
471	Case 28-2007. New England Journal of Medicine, 2007, 357, 1137-1145.	13.9	5
472	Determinación del ancho de distribución eritrocitaria. Utilidad en la insuficiencia cardiaca. Revista Espanola De Cardiologia, 2012, 65, 593-594.	0.6	5
473	Red Cell Distribution Width and Additive Risk Prediction for Major Bleeding in Non–ST-segment Elevation Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2014, 67, 830-836.	0.4	5
474	Can copeptin emerge from the growing shadow of the troponins?. European Heart Journal, 2015, 36, 333-336.	1.0	5
475	Door-to-Furosemide Therapy in the ED. Journal of the American College of Cardiology, 2017, 69, 3052-3054.	1.2	5
476	Breaking Bad. JACC: Heart Failure, 2017, 5, 446-448.	1.9	5
477	"Time Is Muscle" in Acute Heart Failure. JACC: Heart Failure, 2018, 6, 295-297.	1.9	5
478	Endurance exercise training attenuates natriuretic peptide release during maximal effort exercise: biochemical correlates of the "athlete's heart". Journal of Applied Physiology, 2018, 125, 1702-1709.	1.2	5
479	Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. Clinical Cardiology, 2019, 42, 592-604.	0.7	5
480	Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States. Critical Pathways in Cardiology, 2019, 18, 1-4.	0.2	5
481	Application of a machine learning-driven, multibiomarker panel for prediction of incident cardiovascular events in patients with suspected myocardial infarction. Biomarkers in Medicine, 2020, 14, 775-784.	0.6	5
482	Recurrent versus new-onset depressive symptoms: Relationships with biomarkers of cardiovascular health following acute coronary syndrome. Journal of Psychosomatic Research, 2021, 140, 110291.	1.2	5
483	Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure. , 2021, 3, e0480.		5
484	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. JACC: Heart Failure, 2021, 9, 497-505.	1.9	5
485	Using Artificial Intelligence to Better Predict and Develop Biomarkers. Heart Failure Clinics, 2022, 18, 275-285.	1.0	5
486	Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure. Expert Review of Molecular Diagnostics, 2006, 6, 649-662.	1.5	4

#	Article	IF	Citations
487	Troponin I degradation in serum of patients with acute ischemic stroke. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 74-80.	0.6	4
488	What Is the Role of Serial High-Sensitivity Troponin Measurements in Chronic Heart Failure?. Clinical Chemistry, 2012, 58, 1079-1081.	1.5	4
489	Validación de la Barcelona Bio-Heart Failure Risk Calculator en una cohorte de Boston. Revista Espanola De Cardiologia, 2015, 68, 80-81.	0.6	4
490	The International ST2 Consensus Panel: Introduction. American Journal of Cardiology, 2015, 115, 1B-2B.	0.7	4
491	Renin-Angiotensin System Blockade in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 820-822.	1.2	4
492	Manuscripts Based on Datasets Shared by Clinical Research Studies. Journal of the American College of Cardiology, 2017, 69, 1983-1985.	1.2	4
493	Monitoring Biomarkers in Patients Receiving Neprilysin Inhibitors. Current Emergency and Hospital Medicine Reports, 2018, 6, 8-16.	0.6	4
494	Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y 12 Inhibitors in Patients With Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2018, 71, 538-544.	0.4	4
495	A Stitch in Time. JACC: Cardiovascular Interventions, 2018, 11, 2182-2184.	1.1	4
496	Cardiac Troponin and the True–False–Positive. JACC: Case Reports, 2020, 2, 461-463.	0.3	4
497	Multiple Cardiac Biomarker Testing Among Patients With Acute Dyspnea From the ICON-RELOADED Study. Journal of Cardiac Failure, 2022, 28, 226-233.	0.7	4
498	An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.. Journal of Clinical Oncology, 2020, 38, 7550-7550.	0.8	4
499	A Biomarker–Enhanced Model for Prediction of Acute Kidney Injury and Cardiovascular Risk Following Angiographic Procedures: CASABLANCA AKI Prediction Substudy. Journal of the American Heart Association, 2022, 11, e025729.	1.6	4
500	Use of Biomarkers to Predict Cardiac Risk from Medications: Getting to the Heart of the Matter. Clinical Chemistry, 2008, 54, 1107-1109.	1.5	3
501	Sepsis and those who are "weak of heart". Critical Care Medicine, 2008, 36, 3108-3109.	0.4	3
502	Reversed Reverse Remodeling. Circulation: Heart Failure, 2014, 7, 388-390.	1.6	3
503	Cardiac Markers Following Cardiac Surgery and Percutaneous Coronary Intervention. Clinics in Laboratory Medicine, 2014, 34, 99-111.	0.7	3
504	Validation of the Barcelona Bio-Heart Failure Risk Calculator in a Cohort From Boston. Revista Espanola De Cardiologia (English Ed), 2015, 68, 80-81.	0.4	3

#	Article	IF	Citations
505	Light Chains and the Failing Heart. JACC: Heart Failure, 2015, 3, 626-628.	1.9	3
506	Serial Heart Rates, Guideline-Directed Beta Blocker Use, and Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2017, 120, 803-808.	0.7	3
507	Sodium-Glucose Co-Transporter 2 Inhibitors and Insights from Biomarker Measurement in Heart Failure Patients. Clinical Chemistry, 2021, 67, 79-86.	1.5	3
508	Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. Open Heart, 2021, 8, e001704.	0.9	3
509	The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial. ESC Heart Failure, 2021, , .	1.4	3
510	Periprocedural MI as an Endpoint in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 527-529.	1.2	3
511	N‐terminal pro‐B‐type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 87-99.	1.4	3
512	Is acute heart failure a highly prevalent orphan disease?. European Heart Journal, 2006, 27, 2619-2620.	1.0	2
513	Response to Letter Regarding Article, "N-Terminal Pro‐"B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study". Circulation, 2008, 117, .	1.6	2
514	The Role of B-Type Natriuretic Peptide Testing in Guiding Outpatient Heart Failure Treatment. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 397-409.	0.4	2
515	Biomarkers to Predict Risk in Apparently Well Populations. JAMA Cardiology, 2016, 1, 528.	3.0	2
516	Alteration of medical therapy in patients with heart failure relative to change in symptom severity. ESC Heart Failure, 2019, 6, 1085-1087.	1.4	2
517	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Medicine, 2019, 132, S21-S29.	0.6	2
518	<i>De novo</i> heart failure: where the journey begins. European Journal of Heart Failure, 2019, 21, 1245-1247.	2.9	2
519	Are Some Patients With Acute Heart Failure ANP-Deficient?. JACC: Heart Failure, 2019, 7, 899-901.	1.9	2
520	Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure. Clinical Infectious Diseases, 2020, 71, 1306-1315.	2.9	2
521	It is time for consistency in the use of biomarkers in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 90-91.	2.9	2
522	The Need to Innovate and Accelerate Clinical Trial Performance. Journal of the American College of Cardiology, 2020, 76, 14-16.	1.2	2

#	ARTICLE	IF	CITATIONS
523	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	0.7	2
524	Obesity-Mediated Disruption of Natriuretic Peptide–Blood Pressure Rhythms. Journal of the American College of Cardiology, 2021, 77, 2304-2306.	1.2	2
525	The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. Journal of Cardiac Failure, 2021, 27, 1359-1366.	0.7	2
526	Untangling Myocardial Injury. Journal of the American College of Cardiology, 2021, 78, 791-793.	1.2	2
527	The Intersection of Type 2 Myocardial Infarction and Heart Failure. Journal of the American Heart Association, 2021, 10, e020849.	1.6	2
528	Increasingly Sensitive Troponin Assays: Is Perfect the Enemy of Good?. Journal of the American Heart Association, 2020, 9, e019678.	1.6	2
529	First Trimester Cardiac Biomarkers among Women with Peripartum Cardiomyopathy: Are There Early Clues to This Late-Pregnancy Phenomenon?. American Journal of Perinatology, 2023, 40, 137-140.	0.6	2
530	Comparative Prognostic Value of Plasma and Urinary N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Acute Destabilized Heart Failure. Revista Espanola De Cardiologia (English Ed), 2011, 64, 365-372.	0.4	1
531	Red Cell Distribution Width Measurement: What Role Does It Have in Heart Failure?. Revista Espanola De Cardiologia (English Ed), 2012, 65, 593-594.	0.4	1
532	Troponins in equipoise. European Heart Journal, 2016, 37, 3333-3334.	1.0	1
533	Evaluation of the CRUSADE Risk Score for Predicting Major Bleeding in Patients with Concomitant Kidney Dysfunction and Acute Coronary Syndromes. CardioRenal Medicine, 2017, 7, 179-187.	0.7	1
534	Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 185-187.	1.9	1
535	Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. Heart Failure Reviews, 2021, 26, 11-21.	1.7	1
536	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. Cardiac Failure Review, 2021, 7, e06.	1.2	1
537	Utility of High-Sensitivity Troponin Among Stable Patients With Chest Pain Undergoing Stress Imaging (from PROMISE). American Journal of Cardiology, 2021, 158, 148-149.	0.7	1
538	"Rebranding" Natriuretic Peptides. Clinical Chemistry, 2021, 67, 4-5.	1.5	1
539	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 28-36.	0.6	1
540	Risk Prediction Scores in Cardiovascular Disease: Useful Tool or "Model of the Week"?. Journal of Cardiac Failure, 2022, , .	0.7	1

#	Article	IF	Citations
541	Underdiagnosis of Ischemic Heart Disease in New-Onset HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 861-863.	1.2	1
542	Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice. European Journal of Heart Failure, 2022, 24, 678-680.	2.9	1
543	Performance of a protein biomarker panel for prediction of cardiovascular events in patients with diabetes mellitus. European Journal of Preventive Cardiology, 2022, 29, e270-e271.	0.8	1
544	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. Progress in Cardiovascular Diseases, 2022, , .	1.6	1
545	The brain and the cardiovascular system. , 2002, , 1952-1969.		0
546	Use of Natriuretic Peptides in the Diagnosis of Heart Failure. , 0, , 93-115.		0
547	ST2 in Heart Failure: Where Does This New Marker Fit in?. Current Emergency and Hospital Medicine Reports, 2015, 3, 55-61.	0.6	0
548	Moving the Needle Toward a More Personalized Means of Patient Care. JAMA Cardiology, 2018, 3, 1146.	3.0	0
549	Reply. Journal of the American College of Cardiology, 2019, 73, 2121-2122.	1.2	0
550	Race/ethnicity and plasma NT-proBNP in black and white individuals: How it matters. International Journal of Cardiology, 2019, 286, 164-165.	0.8	0
551	Requiem for a Heavyweight. JACC: Heart Failure, 2019, 7, 318-320.	1.9	0
552	Passivating High-Risk Plaques. JACC: Cardiovascular Imaging, 2020, 13, 1561-1563.	2.3	0
553	Biomarkers and Precision Medicine in Heart Failure. , 2020, , 449-466.e3.		0
554	National and Local Politics of the Heart. Journal of the American College of Cardiology, 2021, 77, 1744-1746.	1.2	0
555	Proteomics as a Path to More Refined HeartÂFailure Therapeutics. JACC: Heart Failure, 2021, 9, 278-280.	1.9	0
556	Can biomarkers help find the â€˜sweet spotâ€™ for treating patients with diabetes?. European Journal of Heart Failure, 2021, 23, 1037-1039.	2.9	0
557	Biomarkers and Imaging in Chest Pain. Journal of the American College of Cardiology, 2021, 78, 1418-1420.	1.2	0
558	Biomarkers and Optimal Management of Heart Failure in the Aging Population. , 2014, , 135-146.		0

#	Article	IF	Citations
559	Natriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure. , 2014, , 1-21.		0
560	Natriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure. Biomarkers in Disease, 2015, , 731-756.	0.0	0
561	Abstract 17471: Cardiorenal Syndrome Patients With High NT-proBNP and Cystatin C Levels and Patients With Irreversible Cardiorenal Syndrome Identified by Persistently High Levels of Cystatin C Have Worse Outcomes in Cardiac Resynchronization Therapy: The BIOCRT Study. Circulation, 2015, 132, .	1.6	0
562	Developments in Heart Failure With Reduced Ejection Fractionâ€"Reply. JAMA - Journal of the American Medical Association, 2020, 324, 2215.	3.8	0
563	The Role of Lipoprotein(a) in Cardiovascular Diseasesâ€"Reply. JAMA - Journal of the American Medical Association, 2021, 326, 2078.	3.8	0
564	Multiple biomarkers for rapid rule-out of myocardial infarction: worth the added stress?. European Heart Journal: Acute Cardiovascular Care, 2022, , .	0.4	0
565	21st Century CE. Journal of the American College of Cardiology, 2022, 79, 352-354.	1.2	0
566	Advances in Heart Failure Management: Improving Outcomes With Innovation. Reviews in Cardiovascular Medicine, 2017, 18, S1-S16.	0.5	0